Iq-ai Investors - IQAI

Iq-ai Investors - IQAI

[ADVERT]
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Iq-ai Limited IQAI London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 7.00 08:00:00
Open Price Low Price High Price Close Price Previous Close
7.00 7.00 7.00 7.00 7.00
more quote information »
Industry Sector
GENERAL RETAILERS

Top Investor Posts

DateSubject
20/4/2021
17:53
olde broker: Interesting to read comments made today. Unfortunate aspects that stuck out, one or two of which would not have been tolerated in my day are: 1. Mistakes made in the early paragraphs that indicated poor concentration in drafting; 2. Unnecessarily long and complex such that simple messages are not conveyed; 3. Sufficiency of Working Capital for next 12 months to alleviate fear of the need to raise funds via either a fundraising or a sale of a developing device / methodology; 4. Remark alluding to possible sale or merger (pity BRH paid that whopping dividend !) Additionally, there seems to be a naivety about transitioning from a "penny punting share" into one that attracts the attention of smaller fund managers and analysts. This is sad when we are all aware that Hardman (and others) will write some good research on up & coming companies. Work by such firms is read by smaller fund managers, none of whom like taking stakes in small companies if analysts do not follow them. I have great regard for the CEO's track record and hope that the Company's advisers give focused advice to assist this most interesting company to grow rather than tap into private investors.
06/4/2021
14:44
festario: That news today has now been completely ignored and discounted by the market. ZERO trust in Trevor Brown, lessons learned by serious investors.They won't touch this, and if no one is buying HE can't sell. It's currently impossible to get a quote to sell any.I'll just cling to my basic holding, but will not be adding on any rise or drop.
26/3/2021
14:48
festario: On a similar note, I'm still reeling from the RNS where Trevor, amateurishly, used the word WOW to describe the brain scanning results.You know you're in trouble as an investor when a CEO on uses words like WOW in a corporate regulatory release.If it had been followed up by a quick contract on that, or other IB products, it might just have been justified, but of course it wasn't.It is my belief that Trevor tried to engineer a price rise by that liberal use of language, so he could convert and sell more warrants. But the price actually FELL on that day, and he was thwarted.
25/2/2021
21:40
spurs90: What makes you think he’s trading this surely if he’s sold any wouldn’t that need to be declared? The only Director Dealing and CLN Conversion I see is from 10th December and reads Following Admission, the Company will have 170,107,609 ordinary shares of 0.01p each in issue and Trevor Brown will be directly and indirectly interested in approximately 29.28 per cent of the Company's enlarged issued ordinary share capital. Not sure if you’ve seen he has recently invested in another plc and in discussions with him he has reiterated his on going commitment to IQAI. It’s frustrating watching/waiting trust me I’ve been in here a long time my lowest buy being 1.3p. But I would say we are in the best position ever Mayo Clinic are holding our shares in time this will come good!!! Have a break from time to time GLA
14/1/2021
09:24
bwgs: Agree! TB has lost the trust of so many investors now, not good news for all invested.
09/1/2021
21:38
master rsi: Now is the time to re-think your investing strategy Great waves of creative destruction are set to transform business, creating new superstar companies, laying waste to many traditional investor favourites. Now is the time to re-think your investing strategy. 4 January 2021 2:00pm Author: Michael Baxter Https://www.share.com/stock-markets-and-news/opinion-and-analysis/2021/january/now-is-the-time-to-re-think-your-investing-strategy
06/1/2021
10:53
howdlep: Three excellent posts by VP007 over on LSE. I have combined them here so I can provide a link from Twitter as well:- Incase any investors missed this, I think 2021 will be the year IQAI capitalise on the sevens fold growth of the Telehealth market in the US. Source: hxxps://www.healtheuropa.eu/explosion-in-telehealth-market-due-to-covid-19/100127/ From the 2020 Half Year Report: Teleradiology and Expanding Distribution Since the inception of IQ-AI's subsidiary, Imaging Biometrics™, LLC ("IB, the foundational architectural design strategy of the products has been to build them as platform independent plugins. Steadfast in this approach, IB has successfully translated advanced technologies into portable clinical solutions that readily extend the base functionality of established workstations, medical viewing stations, PACS, and servers. A logical application of the platform-independent design of IB's products is in telehealth. With the onset of Covid-19, healthcare providers had to find new ways to stay connected with patients and administer care. The field of telehealth is exploding and is, for all intents and purposes, and untapped market. During the review period, three licenses of IB Neuro were deployed specifically in teleradiology application. While IB's current products readily lend themselves as natural value-add extensions to established teleradiology platforms, the Company is exploring more direct applications and platforms in the rapidly emerging telehealth space. Watch this space as this could lead to exponential growth for the company... Let’s recap why the share price is completely undervalued. The company has the following products: On the market: IB Clinic 2.0 - FDA, CE Approved IB Clinic consists of perfusion weighted imaging and permeability computation modules IB Neuro and IB DCE, diffusion weighted imaging analysis module IB Diffusion, image co-registration and manipulation module IB Delta Suite, and IB Rad Tech, which streamlines and automates customizable workflows. StoneChecker 2.0 - Approved for US, Europe and South Korea Recently upgraded based on potential client feedback and AI workflows to be included in the next upgrade early this year. Liver Surface Nodularity (LSN) Software - FDA and CE approved LSN's proprietary algorithms process CT images of a patient's liver to assess the nodules along the liver surface. This virtual biopsy offers a low cost, low-risk, non-invasive alternative that may aid in the staging of CLD and has the potential to become the standard of care for a significant global market. IB Stroke - FDA and CE approved A key differentiator for IB Stroke resides in the core Imaging Biometrics' ("IB") algorithms that will be used to generate output commonly used for stroke assessment. Specifically, the ability to automatically quantify blood volume and other perfusion parameters is unique to IB. The initial launch of IB Stroke will be within an IB Rad Tech workflow, which is already installed at leading neurological centres. In the pipeline: IB CAD IB CAD has the potential to detect tumor cells in non-contrast enhancing regions, thus providing the ultimate in early detection, a key advancement for cancer treatment. This technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed. IB Trax - in partnership with the Mayo Clinic This application will leverage the proven ability of quantitative Delta T1 maps, among other technologies, and focus on an improved workflow for evaluating both brain metastases and primary brain cancer across time. For almost a decade, IB's medical advisors and end-users of IB Neuro have considered that the manually intensive way currently used to longitudinally assess brain lesions is cumbersome and prone to error. IB Trax represents an efficient and streamlined platform that will address a significant and immediate need for routine clinical use. Gad Free Imaging Another disruptive technology under development by the Company is the ability to generate a contrast-free MRl image that is equivalent to one acquired with contrast. AI networks have been created and are being trained using only anatomical and functional images free of any exogenous contrast material. The ability to completely eliminate the administration of contrast material has significant benefits on multiple levels. Along with substantial financial savings that can be realised, the on-going concerns about the long-term effects of gadolinium deposition throughout the body can be avoided. Telehealth Since the inception of IQ-AI's subsidiary, Imaging Biometrics™, LLC ("IB, the foundational architectural design strategy of the products has been to build them as platform independent plugins. Steadfast in this approach, IB has successfully translated advanced technologies into portable clinical solutions that readily extend the base functionality of established workstations, medical viewing stations, PACS, and servers. A logical application of the platform-independent design of IB's products is in telehealth. With the onset of Covid-19, healthcare providers had to find new ways to stay connected with patients and administer care. The field of telehealth is exploding and is, for all intents and purposes, and untapped market. During the review period, three licenses of IB Neuro were deployed specifically in teleradiology application. While IB's current products readily lend themselves as natural value-add extensions to established teleradiology platforms, the Company is exploring more direct applications and platforms in the rapidly emerging telehealth space. Distribution / Partnerships Eureka Clinical AI, QMENTA, Blackford Analysis, Medimsight, CorTechs Labs, Arterys, aycan Medical Systems, Pixmeo Grants IB received a five-year, $2.57 million, NIH grant award in collaboration with The Barrow Neurological Institute (BNI), the Mayo Clinic in Arizona, and the Medical College of Wisconsin (MCW). This award follows the previously announced five-year, $2.8 million award IB received in late 2019. Together, these grants provide long-term funding to execute the respective goals and, at current staffing levels, subsidise over 60% of IB's development costs. Additional grants have been submitted to the NIH. All of their products are targeted at $bn markets... ...so taking into consideration all of the above...it’s hard not to believe that the share price will be multiples of where it is today.
29/12/2020
12:28
hedgehogster: Worrying to see that this could head back down to the 5p levels prior to the big spike in November, this is so oversold now with all of the IP it has, I really hope we don't get taken out on the cheap, investors won't see even half of the kind of returns we were all hoping for. AIM always screws over the little guys!
08/12/2020
17:21
digger18: A good summary Festa. Very strange why some people think that they almost have a “right” to make money in a matter weeks when solid sales revenue usually takes months / years. Secondly, directors don’t take risks and invest themselves, without hoping for a return. How many of us would just sit back and sell nothing / repay loans etc when getting a chance? How many investors sell their original stake and then take a free ride? Get real and invest based on fundamentals and opportunities, of which this company has many. FDA approvals do not come easy. Patience! I sit, fully loaded and happy to hold. Mug or not?
08/12/2020
09:08
hedgehogster: I noticed that complete scumbag Trevor has deleted his tweet on Twitter due to the backlash, at least he knows now what all of his suffering investors think of him, pump and dumper! Shame as this business has legs but guess it will be a long while before the next spike
ADVFN Advertorial
Your Recent History
LSE
IQAI
Iq-ai
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210804 00:57:27